CINVANTI is a Intravenous Injection, Emulsion in the Human Prescription Drug category. It is labeled and distributed by Heron Therapeutics, Inc.. The primary component is Aprepitant.
Product ID | 47426-201_53326a74-2dc8-4139-b514-9a61a340c69d |
NDC | 47426-201 |
Product Type | Human Prescription Drug |
Proprietary Name | CINVANTI |
Generic Name | Aprepitant |
Dosage Form | Injection, Emulsion |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2018-01-03 |
Marketing Category | NDA / NDA |
Application Number | NDA209296 |
Labeler Name | Heron Therapeutics, Inc. |
Substance Name | APREPITANT |
Active Ingredient Strength | 130 mg/18mL |
Pharm Classes | Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Neurokinin 1 Antagonists [MoA], Substance P/Neurokinin-1 Receptor Antagonist [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2018-01-03 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA209296 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2018-01-03 |
Ingredient | Strength |
---|---|
APREPITANT | 130 mg/18mL |
SPL SET ID: | 4c218d3a-a508-4abc-9ed8-a6e8e191d1b4 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
47426-201 | CINVANTI | CINVANTI |
0781-2321 | Aprepitant | aprepitant |
0781-2322 | Aprepitant | aprepitant |
0006-0461 | EMEND | aprepitant |
0006-0462 | EMEND | aprepitant |
0006-0464 | EMEND | aprepitant |
0006-3066 | EMEND | aprepitant |
0006-3862 | EMEND | aprepitant |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
CINVANTI 87101607 5419060 Live/Registered |
Heron Therapeutics, Inc. 2016-07-12 |